Table 1.
Maximal effect of intracerebroventricular (i.c.v.) administration of 100 pmol PACAP and VIP on ventilation frequency (fV), ventilation amplitude (
) and total ventilation (
) during the post-injection period
| Pre-injection (0-5 min) | Post-injection | ||||||
| Protocol | N | fV (breaths min−1) | VAMP (a.u.) | VTOT (a.u.) | ΔfV (breaths min−1) | ΔVAMP (a.u.) | ΔVTOT (a.u.) |
| PACAP | 11 | 67.5±3.7 | 27.4±5.0 | 1922±357 | +22.2±4.6*,† | +52.2±8.5*,† | +5407±921*,† |
| VIP | 11 | 64.3±4.1 | 28.2±4.5 | 1909±377 | +9.2±2.7 | +22.2±10 | +2056±874* |
| Pre-injection (0-5 min) | Post-injection | ||||||
| Protocol | N | fV (breaths min−1) | VAMP (a.u.) | VTOT (a.u.) | ΔfV (breaths min−1) | ΔVAMP (a.u.) | ΔVTOT (a.u.) |
| PACAP | 11 | 67.5±3.7 | 27.4±5.0 | 1922±357 | +22.2±4.6*,† | +52.2±8.5*,† | +5407±921*,† |
| VIP | 11 | 64.3±4.1 | 28.2±4.5 | 1909±377 | +9.2±2.7 | +22.2±10 | +2056±874* |
Results for the post-injection period are shown as changes from the baseline (pre-injection, 0-5 min) level.
PACAP, pituitary adenylate cyclase-activating polypeptide; VIP, vasoactive intestinal peptide.
All data are presented as means ± s.e.m. a.u., arbitrary units. Data from trout receiving PACAP and VIP are from Fig. 4 and Fig. 5, respectively. *P<0.05 vs pre-injection values (Dunnett's test); †P<0.05 vs VIP (Student's t-test).